AbbVie is experiencing significant stock growth, reaching $183.90, driven by successful treatments like Humira and Skyrizi. Vertex Pharmaceuticals is gaining attention with shares at $461.68 and its innovative therapies for…
Evaxion Biotech raised $10.8 million through a recent public offering of nearly 4 million ADSs. The offering includes warrants for investors to buy up to 50% more ADSs at $2.71…
Aurion Biotech plans to IPO on the New York Stock Exchange under the ticker "AURN." Challenges include a lawsuit from Alcon Research alleging violations of shareholder rights. Aurion countersued, accusing…
Eledon Pharmaceuticals is based in Irvine, California, and focuses on immune-modulating therapies. Dr. David-Alexandre C. Gros and Dr. Steve Perrin will host a fireside chat on February 5th at the…
Get ready for an exciting peek into the future of pharmaceuticals! On February 5, 2025, ANI Pharmaceuticals, Inc. will take center stage at the illustrious Guggenheim Biotech Conference in New…
Investing in Biotech: The XBI Opportunity The SPDR S&P Biotech ETF, known by its ticker XBI, stands out as a prime investment vehicle within the U.S. biotechnology landscape. Managed by…
**Innovation Takes a Leap Forward** Angelos Stergiou, CEO of SELLAS Life Sciences, has revealed that his team is on the verge of completing a groundbreaking leukemia vaccine. But that's just…
Ascentage Pharma, a key player in the global pharmaceutical landscape, has recently secured an impressive $126.4 million through a U.S. IPO. This substantial funding is primarily earmarked for the advanced…
In this week's episode of the engaging biotech podcast “The Readout LOUD,” critical issues in health and drug development take center stage. The conversation kicks off with reflections on the…
Restructuring Within Biogen's Research Division In a strategic shift following a challenging year, Biogen’s newly appointed research leader, Jane Grogan, Ph.D., is implementing significant adjustments to the company's research team.…